May 05, 2025

FDA Monthly Round-up: Key April Updates

April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.

Conexiant

May 01, 2025

FDA Approves Intranasal DHE for Acute Migraine Relief

The FDA has approved Atzumi for the acute treatment of migraine with or without aura in adults.

Conexiant

April 25, 2025

WHI Funding Restored After Uproar

"We are now working to fully restore funding to these essential research efforts."

Conexiant

April 25, 2025

FDA Approves Penpulimab-kcqx for NPC

The FDA approved penpulimab-kcqx for first line and previously treated recurrent or metastatic non-keratinizing nasopharyngeal carcinoma.

Conexiant

April 24, 2025

FDA Warns of Topical Finasteride Risks

The FDA has issued a safety alert on compounded topical finasteride products, citing adverse events and emphasizing the lack of regulatory approval or safety evaluation.

Conexiant

April 17, 2025

Phase 3 Trial Supports New Gonorrhea Drug

Trial shows oral gepotidacin is non-inferior to ceftriaxone plus azithromycin for treating uncomplicated urogenital gonorrhea.

Conexiant

April 15, 2025

ACIP to Weigh COVID, RSV, Measles Shots

The CDC's expert panel convenes to discuss next-gen COVID-19 shots and vaccination guidelines for various diseases amid a US measles outbreak.

Reuters

June 12, 2024

USPSTF Releases Draft Osteoporosis Screening Guidelines

The USPSTF's draft recommendations reaffirm osteoporosis screening for older women, call for more research on screening men, and address health disparities.

Conexiant

July 24, 2024

World Bank's Pandemic Fund Raises $700M from U.S., Germany

The World Bank's Pandemic Fund secures substantial contributions from the U.S. and Germany, aiming to prevent a recurrence of a crisis similar to COVID-19.

Reuters